Henrik Schmidt
LightNews LightNews
banner
henrik-hs.bsky.social
Henrik Schmidt
@henrik-hs.bsky.social
3 followers 5 following 2 posts
VP, Commercial - Europe & APAC @ Myllia Biotechnology - Your boutique biotech partner in Vienna, Austria focused on high-content CRISPR screens in primary human cells for AI-ready drug target discovery
Posts Replies Media Videos
Reposted by Henrik Schmidt
mylliabio.bsky.social
Are you interested in single-cell genomics, AI-ready perturbation data and virtual cell models? The registration for the "High-Content CRISPR Screening" conference in March 2026 is open via the website:

perturb2026.bio

Meet the Speaker: Ci Chu
Dr. Ci Chu is the Senior Vice President of AI-Enabled Discovery at Xaira Therapeutics, where he leads the team building the massive biological data generation engine fueling Xaira's generative AI models. With over a decade of experience working at the intersection of discovery biology and AI/ML, he has previously led high-impact functional genomics and multi-modal phenotyping teams at insitro, Verily and Google X.
December 2, 2025 at 9:13 AM
Reposted by Henrik Schmidt
mylliabio.bsky.social
We’re excited to announce the expansion of Myllia’s commercial team: Neil Matharoo has joined as VP, Commercial, North America, and Henrik Schmidt has been promoted to VP, Commercial, Europe & APAC. At @mylliabio.bsky.social, we’ve built a unique, scalable CRISPR screening platform!
We’re excited to announce the expansion of Myllia’s global commercial leadership team: Neil Matharoo has joined as VP, Commercial, North America, and Henrik Schmidt has been promoted to VP, Commercial, Europe & APAC. Their expertise strengthens our ability to support partners worldwide as we advance next-generation CRISPR screening technologies! At Myllia Biotechnology, we’ve built a unique, scalable CRISPR screening platform: - Unbiased drug target discovery powered by high-throughput, pooled CRISPR screening - Primary human cell models that translate in vivo, e.g., T helper cells and myeloid cells - Single-cell resolution for deeply resolved functional genomics Get in touch via info@myllia.com and come join the “High-Content CRISPR Screening” conference in March 2026: www.perturb2026.bio #TeamMyllia #CRISPR #FunctionalGenomics #DrugDiscovery
November 25, 2025 at 9:21 AM
Reposted by Henrik Schmidt
mylliabio.bsky.social
Are you interested in single-cell genomics and drug target discovery? The "High-Content CRISPR Screening" conference will take place from March 18-19, 2026, in Vienna, Austria.

Conference website: perturb2026.bio

Meet the Speaker: @thijnbrummel.bsky.social
Dr. Thijn Brummelkamp is Director of Research at the Netherlands Cancer Institute with a research interest in the fields of cell biology and cancer biology. Thijn uses genetics in human cells to identify genes important for human disease. During his Ph.D. studies, Thijn developed a system for expressing shRNA molecules, which allowed for long-term gene inhibition. He used this to carry out the first RNA interference-based screen in human cells, revealing the function of the CYLD tumor suppressor gene. His lab also developed haploid human cells as a genetic model system, using this approach to discover host factors for pathogens, such as the cholesterol transporter NPC1 as the long-sought entry receptor for the Ebola virus. More recently, he has applied haploid genetics to uncover missing enzymes and alternative cellular pathways, leading to the discovery of the elusive enzyme crucial for mature actin production, an alternative triglyceride synthesis pathway, and a pathway that explains DNA damage-induced cancer cell death in the absence of p53.
November 24, 2025 at 11:06 AM
Reposted by Henrik Schmidt
mylliabio.bsky.social
Myllia Biotechnology is heading to @elrig.org Drug Discovery 2025! Meet with Lukas Badertscher, Stefanie Fellinger, and Henrik Schmidt to explore CRISPR-based functional genomics for drug target discovery.

Spotlight Talk, Day 1, 12.40 PM
Posters #3, #45, and #107
Booth D02
October 14, 2025 at 3:55 PM
Reposted by Henrik Schmidt
mylliabio.bsky.social
Are you interested in single-cell genomics, multi-modal perturbation data and drug target discovery? We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place from March 18-19, 2026, in Vienna, Austria!

Meet the Speaker: Radu Rapiteanu

www.perturb2026.bio
Dr. Radu Rapiteanu is a Director of Target Discovery at GSK spearheading target identification and validation strategies across respiratory, kidney, autoimmune, and infectious diseases. He leads global projects and teams at the interface between functional genomics, genetics and single-cell technologies. He specialises in the design and implementation of genetic (CRISPR) and chemogenomic screening campaigns in human primary cells and complex models. Radu holds a Ph.D. from the University of Cambridge. He is a passionate about translating cutting edge technologies into novel therapies.
October 2, 2025 at 8:24 AM
Reposted by Henrik Schmidt
mylliabio.bsky.social
The "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria.

The registration is now open via the conference website:
perturb2026.bio

Meet the Speaker: Mathew Garnett

@mgarnett.bsky.social
Dr. Mathew Garnett is a Senior Group Leader at the Wellcome Sanger Institute whose research focuses on understanding cancer biology and translating discoveries into new therapies. Early in his career, he helped identify the BRAF cancer gene and revealed key mechanisms regulating cell division and drug responses. His laboratory has pioneered systematic drug and CRISPR screening in cancer models, leading to the identification of treatment biomarkers, new therapeutic targets, and the development of the Cancer Dependency Map. Dr Garnett’s team also established one of the world’s largest biobanks of tumour organoids, contributing extensively to the Human Cancer Model Initiative. A key discovery from his lab identified Werner syndrome helicase as a target in microsatellite unstable cancers, now driving clinical development of WRN inhibitors. Beyond academia, he co-founded Mosaic Therapeutics to advance precision oncology, and his research continues to shape cancer research and drug discovery.
September 29, 2025 at 12:32 PM
Reposted by Henrik Schmidt
mylliabio.bsky.social
Meet Myllia's @henrik-hs.bsky.social at #BioJapan2025 in Yokohama, Tokyo from October 8-10 to discuss your next CRISPR-based drug target discovery partnerships!

Websites:
myllia.com
myllia.com/events/bio-j...

Contact us via email: info@myllia.com
Myllia Biotechnology is looking forward to explore new collaborations in early-stage drug target discovery and CRISPR-based functional genomics: Meet Henrik Schmidt at 📍 BioJapan 2025 in Yokohama, Tokyo from October 8-10 to discuss your next drug discovery partnerships! At Myllia, we perform high-content CRISPR screens in primary human cells, incl. epithelial cells, T cells, dendritic cells and macrophages. Our technology platform enables the systematic identification of genetically validated, high-value targets in autoimmune disease, inflammation and oncology. 📰 Visit www.myllia.com for more information 📩 Contact us via email: info@myllia.com
September 22, 2025 at 11:22 AM
henrik-hs.bsky.social
Exciting times ahead for @mylliabio.bsky.social in Q4 2025

📍 BIO Japan 2025 - Tokyo, 8-10 October
📍 ELRIG Drug Discovery 2025 - Liverpool, 21-22 October
📍 BIO Europe 2025 - Vienna, 3-5 November

📰 Website: www.myllia.com
📩 Contact: info@myllia.com
Meet Myllia at: 📍 BIO Japan 2025 - Tokyo, 8-10 October 📍 ELRIG Drug Discovery 2025 - Liverpool, 21-22 October 📍 BIO Europe 2025 - Vienna, 3-5 November
September 8, 2025 at 8:23 AM
Reposted by Henrik Schmidt
mylliabio.bsky.social
🧬 Meet #TeamMyllia

Our mission is to accelerate drug discovery through high-content CRISPR screening:

- 150+ CRISPR screens in cell lines and primary cells
- 35+ collaborative projects worldwide
- End-to-end workflows from screening to bioinformatics

www.myllia.com
At Myllia, our mission is to accelerate drug discovery through high-content CRISPR screening. Since our founding in 2018 by Thomas Moser (CEO), Tilmann Buerckstuemmer (CSO), and Christoph Bock (Scientific Advisor), we have partnered with biotech and pharmaceutical companies globally to support their drug discovery programmes. We are committed to identifying and validating drug targets through CRISPR screening in the most biologically relevant cellular models:   - 150+ CRISPR screens in cell lines and primary human cells - 35+ collaborative projects worldwide - End-to-end workflows from experimental screening to computational analysis Our platform integrates multiple CRISPR modalities with primary human cell types, combined with high-content readouts such as single-cell RNA-Seq, CITE-Seq, FACS, and fitness assays. 👇 Are you curious how functional genomics can transform drug discovery? Follow us for updates & insights, and check out www.myllia.com
August 21, 2025 at 11:21 AM
Reposted by Henrik Schmidt
mylliabio.bsky.social
📢 @mylliabio.bsky.social is heading to #IUIS2025 - we’re excited to share that Anke Loregger, Myllia’s Director of R&D, will attend the International Congress of Immunology (IUIS) 2025 in Vienna! Interested in the VISTA platform?

Poster: II.265 on Wednesday, August 20 at 12.15 PM

www.myllia.com
August 11, 2025 at 1:22 PM
Reposted by Henrik Schmidt
mylliabio.bsky.social
🧬 Unlocking target discovery in primary human dendritic cells with VISTA™

At @mylliabio.bsky.social, we’re enabling functional genomics in primary immune cells. Our VISTA™ platform combines pooled CRISPRi with scRNA-Seq to systematically map gene function at scale!

Contact us via: info@myllia.com
August 5, 2025 at 2:02 PM
Reposted by Henrik Schmidt
mylliabio.bsky.social
🗓️ @mylliabio.bsky.social sponsors the first conference on "High-Content CRISPR Screening" from March 18-19, 2026 in Vienna: perturb2026.bio

Scientific topics:
🔬 CRISPR-based screening strategies
🧬 Perturb-Seq & CROP-Seq
💻 Computational analyses
💻 AI models of human cells
📸 Image-based screens
August 7, 2025 at 11:46 AM
henrik-hs.bsky.social
Looking forward to representing @mylliabio.bsky.social at the #SwissBiotechDay 2025 in Basel and discussing drug target ID/validation powered by single-cell CRISPR screens in primary human cells!

🎯 Explore Myllia's platform: myllia.com
📩 Contact: info@myllia.com

#TeamMyllia #CRISPR #scRNASeq
April 15, 2025 at 3:04 PM
Reposted by Henrik Schmidt
mylliabio.bsky.social
We will be at #AACR25 in Chicago, USA

Poster presentation: "A compressed genome-wide CROP-Seq screen to dissect the polarization of THP-1-derived macrophages"

🎯 When: Sunday, April 27 from 2.00 - 5.00 PM EST
🎯 Poster: LB043, Section 52

myllia.com
#CRISPR #scRNASeq #TargetDiscovery #FGX
April 8, 2025 at 2:14 PM
Reposted by Henrik Schmidt
mylliabio.bsky.social
🚀 At @mylliabio.bsky.social, we're advancing scRNA-Seq in primary human cells with our targeted sequencing (TA-Seq) platform!

Key insights:
• TA-Seq uses 10K reads/cell vs. 50K reads/cell for WTA
• Low-abundance mRNAs are detected more effectively w/ TA-Seq & multiplexed primer panels

myllia.com
March 5, 2025 at 10:46 AM
Reposted by Henrik Schmidt
mylliabio.bsky.social
A team at @mylliabio.bsky.social contributed one of the largest single-cell #CRISPR #perturbation #screens published today: nature.com/articles/s41...

The lab of Wei Li developed the perturbation-response score (PS) allowing the quantification of diverse perturbation responses in single cells!
Decoding heterogeneous single-cell perturbation responses - Nature Cell Biology
In two independent studies, Song et al. and Jiang, Dalgarno et al. present computational frameworks, perturbation-response score and Mixscale, respectively, to determine individual cellular variation ...
nature.com
February 26, 2025 at 12:24 PM
Reposted by Henrik Schmidt
mylliabio.bsky.social
🧬 At @mylliabio.bsky.social, we're pushing the boundaries of #scCRISPR screens in primary human T cells. For example, we focus on scalable #CROPSeq screens to uncover key mediators of T helper cell differentiation, particularly Th2 cells!

Reach out via: myllia.com/contact/
#CRISPR #scRNASeq #TCells
February 14, 2025 at 11:56 AM
Reposted by Henrik Schmidt
mylliabio.bsky.social
📢 One month to go! @mylliabio.bsky.social will be at #BIOEuropeSpring 2025 in Milan, Italy! Would you like to get in touch? Meet our BD Manager @henrik-hs.bsky.social on site to explore #CRISPR-based #functional #genomics screens in primary human cells!

Learn more about CROP-Seq here: myllia.com
February 11, 2025 at 3:19 PM
Reposted by Henrik Schmidt
mylliabio.bsky.social
Can #AI predict #CRISPR perturbation outcomes?

@mylliabio.bsky.social's CROP-Seq dataset provides a critical resource for AI-driven #Foundation #Models of the Human Cell: myllia.com/resources/cr...

We're the global leader in CRISPR-based functional genomics screens - contact us via info@myllia.com
February 3, 2025 at 3:36 PM
Reposted by Henrik Schmidt
mylliabio.bsky.social
🔬 At @mylliabio.bsky.social, we're revolutionizing target discovery with CROP-Seq in primary human T cells:

- Custom assay development
- SLICE protocol for functional screening
- Integration of CITE-Seq & scRNA-Seq

Ready to elevate your research? Contact us at info@myllia.com and visit: myllia.com
January 23, 2025 at 11:15 AM